We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Moderna Inc | NASDAQ:MRNA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.23 | -0.18% | 125.36 | 125.00 | 125.48 | 126.3843 | 122.01 | 125.06 | 4,513,134 | 01:00:00 |
1. Name and Address of Reporting Person * Flagship Ventures Fund IV General Partner LLC | 2. Issuer Name and Ticker or Trading Symbol Moderna, Inc. [ MRNA ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) |
3. Date of Earliest Transaction
(MM/DD/YYYY)
| ||
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
1.Title of Security (Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 5/21/2020 | S | 223314 | D | $65.7661 (1) | 22603085 | I | See Footnote (2) | ||
Common Stock | 5/21/2020 | S | 121771 | D | $67.1504 (3) | 22481314 | I | See Footnote (2) | ||
Common Stock | 5/21/2020 | S | 39082 | D | $68.8144 (4) | 22442232 | I | See Footnote (2) | ||
Common Stock | 5/21/2020 | S | 20492 | D | $70.4564 (5) | 22421740 | I | See Footnote (2) | ||
Common Stock | 5/21/2020 | S | 13408 | D | $71.5141 (6) | 22408332 | I | See Footnote (2) | ||
Common Stock | 5/21/2020 | S | 1933 | D | $72.4351 (7) | 22406399 | I | See Footnote (2) | ||
Common Stock | 5/21/2020 | S | 42540 | D | $65.7661 (1) | 6538226 | I | See Footnote (8) | ||
Common Stock | 5/21/2020 | S | 23199 | D | $67.1504 (3) | 6515027 | I | See Footnote (8) | ||
Common Stock | 5/21/2020 | S | 7443 | D | $68.8143 (4) | 6507584 | I | See Footnote (8) | ||
Common Stock | 5/21/2020 | S | 3900 | D | $70.4564 (5) | 6503684 | I | See Footnote (8) | ||
Common Stock | 5/21/2020 | S | 2551 | D | $71.5144 (6) | 6501133 | I | See Footnote (8) | ||
Common Stock | 5/21/2020 | S | 367 | D | $72.4355 (7) | 6500766 | I | See Footnote (8) | ||
Common Stock | 5/22/2020 | S | 363594 | D | $69.4465 (9) | 22042805 | I | See Footnote (2) | ||
Common Stock | 5/22/2020 | S | 56406 | D | $70.1761 (10) | 21986399 | I | See Footnote (2) | ||
Common Stock | 5/22/2020 | S | 69254 | D | $69.4465 (9) | 6431512 | I | See Footnote (8) | ||
Common Stock | 5/22/2020 | S | 10746 | D | $70.1762 (10) | 6420766 | I | See Footnote (8) | ||
Common Stock | 11460435 | I | See Footnote (11) | |||||||
Common Stock | 3924 | I | See Footnote (12) | |||||||
Common Stock | 1389827 | I | See Footnote (13) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
Flagship Ventures Fund IV General Partner LLC C/O FLAGSHIP PIONEERING, INC. 55 CAMBRIDGE PARKWAY, SUITE 800E CAMBRIDGE, MA 02142 | X | X | |||
Flagship Ventures Fund IV, L.P. 55 CAMBRIDGE PARKWAY, SUITE 800E CAMBRIDGE, MA 02142 | X | ||||
Flagship Ventures Fund IV-Rx, L.P. 55 CAMBRIDGE PARKWAY, SUITE 800E CAMBRIDGE, MA 02142 | X | ||||
AFEYAN NOUBAR 55 CAMBRIDGE PARKWAY, SUITE 800E CAMBRIDGE, MA 02142 | X | X |
Signatures | ||
Flagship Ventures Fund IV General Partner LLC, By: /s/ Noubar B. Afeyan, Ph.D., Name: Noubar B. Afeyan, Ph.D., Title: Manager | 5/26/2020 | |
**Signature of Reporting Person | Date | |
Flagship Ventures Fund IV, L.P., By: Flagship Ventures Fund IV General Partner LLC, By: /s/ Noubar B. Afeyan, Ph.D., Title: Manager | 5/26/2020 | |
**Signature of Reporting Person | Date | |
Flagship Ventures Fund IV-Rx, L.P., By: Flagship Ventures Fund IV General Partner LLC, By: /s/ Noubar B. Afeyan, Ph.D., Title: Manager | 5/26/2020 | |
**Signature of Reporting Person | Date | |
Noubar B. Afeyan, Ph.D. By: /s/ Noubar B. Afeyan, Ph.D. | 5/26/2020 | |
**Signature of Reporting Person | Date |
1 Year Moderna Chart |
1 Month Moderna Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions